Hyoscine butylbromide (Butylscopolamine bromide)

except when recommended for injectable use

Approval Date: August 23, 2016

Schedule: II

Footnote:

Canadian Pharmacy Regulatory Authorities:

Contact

Mailing Address:
M615–1554 Carling Avenue
Ottawa, Ontario K1Z 7M4 Canada

Phone: 1 (613) 569-9658
info@napra.ca

Receive NAPRA updates of interest directly to your inbox: general NAPRA news, NDS updates and/or updates on practice resources.